Nonselective versus selective β-blockers in the management of chronic heart failure: Clinical implications of the Carvedilol or Metoprolol European Trial

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Greenberg, Barry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

blockers; Carvedilol; Chronic heart failure; COMET; Metoprolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL TARTRATE; PROPRANOLOL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; LOW DRUG DOSE; MALE; RECEPTOR BLOCKING; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL;

EID: 3042623640     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
2. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
3. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine aetivation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
4. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of the International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999; 353:9-13.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
7. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol Cr/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
8. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
9. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83:1A-38A.
10. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail. 1999; 5:357-382.
11. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:IV40-IV48.
12. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1989;59:297-309.
13. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
14. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet. 1990;336:1-6.
15. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
16. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-2988.
17. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
18. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
19. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol. 1999;33:1926-1934.
20. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899-907.
21. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
22. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality and morbidity in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
23. Kukin ML, Kalman J, Mannino M, et al. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta-blockade alone in chronic congestive heart failure. Am J Cardiol. 1996;77:486-491.